Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYB507 vs Omalizumab in Refractory Chronic Spontaneous Urticaria
CTR20231164Phase 3Completed
- Sponsor
- Sichuan Yuanda Shuyang Pharmaceutical
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by Sichuan Yuanda Shuyang Pharmaceutical. Started Apr 2023; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20231164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231164.